Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation
Copyright © 2023 Elsevier Inc. All rights reserved..
The authors summarize recent updates in the prevention and management of cytomegalovirus (CMV) in solid organ transplant (SOT) recipients with a focus on CMV seronegative recipients of organs from seropositive donors (CMV D+/R-) who are at highest risk of CMV infection and disease. They discuss advantages of preemptive therapy for CMV disease prevention in CMV D+/R- liver transplant recipients, letermovir for CMV prophylaxis, and updates in the development of monoclonal antibodies and vaccines as immune-based preventative strategies. They review the roles of maribavir and virus-specific T cells for management of resistant or refractory CMV infection in SOT recipients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Infectious disease clinics of North America - (2023) vom: 20. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Doss, Kathleen M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytomegalovirus (CMV) |
|---|
| Anmerkungen: |
Date Revised 27.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.idc.2023.10.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364809167 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364809167 | ||
| 003 | DE-627 | ||
| 005 | 20240327235446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.idc.2023.10.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1350.xml |
| 035 | |a (DE-627)NLM364809167 | ||
| 035 | |a (NLM)37989636 | ||
| 035 | |a (PII)S0891-5520(23)00083-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Doss, Kathleen M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a The authors summarize recent updates in the prevention and management of cytomegalovirus (CMV) in solid organ transplant (SOT) recipients with a focus on CMV seronegative recipients of organs from seropositive donors (CMV D+/R-) who are at highest risk of CMV infection and disease. They discuss advantages of preemptive therapy for CMV disease prevention in CMV D+/R- liver transplant recipients, letermovir for CMV prophylaxis, and updates in the development of monoclonal antibodies and vaccines as immune-based preventative strategies. They review the roles of maribavir and virus-specific T cells for management of resistant or refractory CMV infection in SOT recipients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cytomegalovirus (CMV) | |
| 650 | 4 | |a Letermovir | |
| 650 | 4 | |a Maribavir | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Solid organ transplant | |
| 650 | 4 | |a Vaccines | |
| 650 | 4 | |a Virus-specific T cells (VST) | |
| 700 | 1 | |a Heldman, Madeleine R |e verfasserin |4 aut | |
| 700 | 1 | |a Limaye, Ajit P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious disease clinics of North America |d 1996 |g (2023) vom: 20. Nov. |w (DE-627)NLM012614386 |x 1557-9824 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:20 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.idc.2023.10.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 20 |c 11 | ||